APRESOLINE
LOE ApproachingNDAORALTABLETPriority Review
Approved
Jan 1953
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
APRESOLINE is an oral small-molecule tablet approved in 1953 as an NDA by Novartis. The specific indication and mechanism of action are not disclosed in available data. This is a legacy product nearing loss of exclusivity.
LOE Approaching
Product is in late-stage lifecycle with minimal linked job openings; career growth on this brand is constrained.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect a legacy product in decline with shrinking team footprint. Career opportunities are focused on managing LOE transition and defending market share against generics rather than growth initiatives.
Brand ManagerMarket Access Manager
Worked on APRESOLINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.